Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT];
theranostics in the field of precision oncology;
radiopharmaceutical products, namely lutetium-containing precursors;
solutions for radioactive labelling;
radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours;
target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope;
radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC;
177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET];
radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer;
radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications;
Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases;
radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases.